Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Amlodipine Oral Solution vs Norvasc
NCT05808725Phase 1Completed
- Sponsor
- Brillian Pharma Inc.
- Start
- Dec 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of amlodipine in hypertension (HTN) and coronary artery disease (CAD) (3 arms), sponsored by Brillian Pharma Inc. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve to the last measurable concentration up to 50 days and 1 more. Started Dec 2022; status: completed.
02
Drugs
amlodipine
03
Conditions
hypertension (HTN)coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT05808725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05808725.